Abbott’s Hytrin
Executive Summary
Alpha blocker designated "approvable" by FDA for treatment of symptoms of benign prostatic hyperplasia Aug. 12. The new indication for Hytrin (terazosin) was recommended for approval by FDA's Endocrinologic and Metabolic Drugs Advisory Committee March 1 ("The Pink Sheet" March 8, p. 3).